Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET).
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: J. A. Chan, D. P. Ryan, C. S. Fuchs, A. X. Zhu, T. A. Abrams, B. M. Wolpin, P. Malinowski, E. Regan, M. Kulke
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2591254987